

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>06275-461US1</b>	Application No. <b>10/542,326</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Alan Wellington Faull et al.</b>	
		Filing Date <b>July 13, 2005</b>	Group Art Unit <b>1626</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AC	Karen, M. et al. "NF-kB in cancer: from innocent bystander to major culprit," <u>Nat. Rev. Cancer</u> , 2: 301-310 (2002)
	AD	Luo et al., "IKK/NF-kB signaling: balancing life and death – a new approach to cancer therapy," <u>J. of Clin. Inv.</u> , 115:10: 2625 (2005)
	AE	Orlowski, et al., "NF-kB as a therapeutic target in cancer," <u>TRENDS in Mol. Med.</u> , 8:8: 385 (2002)
	AF	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	